Financial Statements
for the Fiscal Year Ended March 31, 2016
(From Apr. 1, 2015 to Mar. 31, 2016)
Summary of consolidated results
JMS Co., Ltd.
Company Code No. 7702
May 13, 2016
1
Highlights in Business Results
(unit: JPY million)
Apr. - Mar. 2015
Results
Sales
Apr. - Mar. 2016
Results
Diff.
Year– over – Year
55,401
57,636
2,235
4.0%
Operating Income
378
1,422
1,043
275.3%
Ordinary Income
373
1,252
879
235.4%
Profit attributable to
owners of parent
139
754
615
442.5%
JPY 2.85
JPY 15.48
---
---
US Dollar
109.93
120.14
Euro
140.42
134.31
Singapore Dollar
85.21
86.70
Net Income per share
Exchange Rate
(average during
period)
(unit: JPY)
-Increase of gross profit due to a sales increase
-Reduction of contribution of the cost as well as favorable
foreign exchange conditions
Dividend
forecast
Overseas
-Continued growth in the sales of apheresis kits
-Increased sales of AV fistula needles
Profit
Japan
Sales
-Launch of blood bags with leukocyte reduction filter
-Increased sales of cardiopulmonary equipment
Increased in sales (12th straight
year) and profit for the FYE Mar.
2016
-Annual dividend: JPY 10 per share
(Interim dividend JYP 4 per share and year-end dividend
JYP 6 including commemorative dividend of JYP 2 for the
50th anniversary)
2
Sales by segment (geographical area)
Apr. – Mar. 2015
(unit: JPY million)
42,145
Apr. – Mar. 2016
Sales incl. internal transaction
40,412
40,000
Sales for third party
36,199
37,233
18,766 20,259
20,000
10,000
9,568
10,389
3,896
1,564
0
Japan
Southeast Asia
4,158
1,688
China
3,398
3,318
3,395
3,315
Germany
2,830
3,133
2,830
3,133
United States
1,843
1,843
1,875
1,875
Others
3
Profit by segment (geographical area)
Apr. – Mar. 2016
Apr. – Mar. 2015
(unit: JPY million)
1,200
855
800
563
373
400
293
105
63
117
31
0
(3)
(73)
(17)
(400)
(388)
Japan
Southeast Asia
China
Germany
United States
Others
4
Summary by segment (geographical area)
Sales
Ordinary Income
Japan
Ordinary Income
JPY mil.
4.3%
563
JPY mil.
432.7%
20,259
JPY mil.
8.0%
855
JPY mil.
1,239.5%
-Continued growth in the sales of apheresis kits for North
America raised net sales
-Favorable currency impact on sales in foreign currency
transaction resulted in a profit
Sales
Ordinary Ioss
China
42,145
-Increased sales of cardiopulmonary equipment as well as
launch of blood bags with leukocyte reduction filter raised
net sales
-The influence of sales increase and cost reduction in
addition to dividends received resulted in a profit
Sales
Southeast
Asia
( %: year-over-year )
4,158
JPY mil.
6.7%
(73)
JPY mil.
－%
Blood bags with leukocyte reduction filter
It is a blood bag used for blood storage and
blood transfusion collected by blood
donation. It has a filter to reduce leukocyte
which is one of the reasons that cause side
effects after blood transfusion.
-Strong sales of Infusion Set for Japan market raised net
sales
-Unfavorable currency impact on the sales on a yen basis
transaction resulted in a loss
5
Summary by segment (geographical area)
Sales
Ordinary Income
Germany
JPY mil.
(2.3%)
293
JPY mil.
(21.4%)
( %: year-over-year )
-Increased sales of AV fistula needles for hemodialysis in
Europe was offset by decrease of sales in yen equivalent
by strong yen, reducing net sales
-Higher import cost with weak Euro resulted in a profit
Sales
Ordinary Income
United States
3,318
3,133
JPY mil.
10.7%
117
JPY mil.
－%
-Strong sales of AV fistula needles for South and Central
America market raised net sales
-The influence of reduced provision for allowance for
doubtful accounts led to a profit
Sales
1,875
JPY mil.
1.8%
Ordinary Ioss
(388)
JPY mil.
－%
AV Fistula Needle
AV fistula needle is for pulling blood from a
patient during a dialysis therapy.
Others
6
Sales by Business Segment
Apr. – Mar. 2015
(unit: JPY million)
30,000
26,578
Apr. – Mar. 2016
27,883
25,000
20,000
17,895 18,336
15,000
10,000
4,562
5,000
4,574
4,470
4,863
1,894
1,977
0
Infusion and
Transfusion
Dialysis
General Medical
Supplies
Cardiovascular
Others
7
Sales by Segment (Customer's Location)
Apr. – Mar. 2015
(unit: JPY million)
40,000
35,502
Apr. – Mar. 2016
Others
3%
36,766
Asia・Oceania
14%
30,000
Europe
8%
Apr. – Mar.
2016
20,000
North America
11%
Japan
64%
7,733
10,000
5,553
6,707
4,682
8,014
4,424
1,929
1,723
0
Japan
North America
Europe
Asia・Oceania
Others
8
Selling, General and Admin. Expenses
(unit: JPY million)
15,000
50%
13,073
13,444
12,000
30%
23.6%
23.3%
20%
Apr. - Mar.
2016
Labor Cost
5,669
5,780
111
2.0%
Transport
1,581
1,647
66
4.2%
R&D
1,215
1,258
42
3.5%
428
412
(15)
(3.7%)
4,178
4,346
167
4.0%
13,073
13,444
371
2.8%
Depreciation
Others
3,000
0
10%
Apr. - Mar. Apr. - Mar.
2015
2016
Year
-overYear
Apr. - Mar.
2015
40%
9,000
6,000
(unit: JPY million)
Total
Diff.
0%
9
Ordinary Income: Compared with the previous year
Minus factor Plus factor
Ordinary
Income
Apr.-Mar. 2015
(unit: JPY million)
373
Increase of
Gross Profit
820
Ordinary
income
increased
JPY 879 million
（287）
Increase of SGA
Increase of
Non-operating profit
25
320
Ordinary
Income
Apr.-Mar. 2016
Impact of
Exchange rate
1,252
The underlined figures exclude impact of exchange rate.
10
Forecast for FYE Mar. 2017
(unit: JPY million)
FYE Mar. 2016
FYE Mar. 2017
Result
Forecast
Sales
Year-over-Year
57,636
58,000
0.6%
Operating Income
1,422
1,100
(22.7%)
Ordinary Income
1,252
1,100
(12.2%)
754
600
(20.5%)
JPY 15.48
JPY 12.31
---
US Dollar
120.14
110.00
---
Euro
134.31
125.00
---
Singapore Dollar
86.70
82.00
---
Profit attributable to
owners of parent
Net Income per share
Exchange Rate (average during period)
Influence of appreciation of the yen, reduction in reimbursement price, and depreciation burden due to new plant establishment
and plant extension is estimated. Strive to develop to the business promptly with increased production capacity.
11
Topics < Apr. 2016 – May. 2016 >
-Holding the completion ceremony of the new facility of Izumo Plant.
May. 6, 2016
-Holding the inauguration ceremony of JMS Healthcare PHL, Inc. .
Apr. 25, 2016
Izumo Plant
JMS Healthcare PHL, Inc.
A white building of the top right corner the new facility
12
The Bridge to Good Health Care
The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.
13